• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » French government replaces health products agency, gives additional powers

French government replaces health products agency, gives additional powers

May 2, 2012
CenterWatch Staff

The French government has replaced the French Food Safety Agency of Health Products with the new National Security Agency of Medicines and Health Products (MSNA).

The MSNA’s internal organization is still under development and will be effective in a few months. In an effort to break down barriers, the new agency’s five business divisions—legal and regulatory affairs, evaluation, monitoring, control, inspection—will operate together for greater efficiency and responsiveness.

The new agency—more than just a name change—will also establish a new mode of governance. As per a law passed on December 29, 2011, the agency will be given additional powers to fully facilitate the country’s needs. These powers include increased involvement and resources for monitoring and evaluating health products, such as the ability to encourage the development of independent research focused on the safety of products. The new powers also extend to leadership requirements, such as limiting off-label prescriptions through recommendations of temporary use (RTU), reducing the number of temporary authorizations for use (ATU) and priori control of advertising to health professionals for human medicines.

The law also set the MSNA’s requirements, including:

  • Transparency — traceability of work before decision making, recording sessions and publication of reports
  • Independence of the experts participating in the work of the agency
  • Sharing information with everyone (healthcare professionals, patients, general public). The MSNA will post online all results of clinical trials that led to issuance of a marketing authorization through the creation of a directory site agency. All MSNA decisions will be made known to all, appropriately to the needs and expectations

The MSNA’s operating and investment budget will be 25% higher than its predecessor’s and will be financed exclusively by a state subsidy rather than through taxes or fees from manufacturers.

The agency’s board of directors will consist of a chairman, nine state representatives, three deputies, three senators, two representatives of health insurance, a representative of the National Medical Association and the National Order of Pharmacists, two representatives of user associations in the health system, two qualified staff and three representatives of MSNA. With the exception of state representatives, members of the board will be serve three-years terms, renewable once.

The MSNA’s scientific council will consist of eight members appointed based on their scientific expertise in the field of health products, four other prominent scientists with expertise in the field of health products, and a doctor, a biologist and a hospital pharmacist designated by their order. Members of the council will also serve three-year terms and will be appointed by the Minister of Health.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing